Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO. Need analyze transcript. Question asks: Does management convey that company today is running on different basis than reported results/reputation built on? Both halves: (1) change of basis already real, (2) management says record/perception lag change. Need use only transcript. Need decide. Let's parse. Amgen Q3 2018. Management discusses portfolio transition, new products, biosimilars, pipeline. Bob: "we're in midst of high volatility... fundamental objectives intact." "We've said for some time expected growing pressures on drug prices... With price under pressure, having innovative products which can deliver volume growth... ever more important. We have several such products... new and recently launched products had double-digit unit volume growth." "We believe differentiated products like Prolia, Repatha and Aimovig offer attractive long-term growth prospects." "Our new product story continues to unfold with Aimovig... shaping up to be one of industry's most successful recent launches." "We believe biosimilars can be important growth driver... now launching KANJINTI... AMGEVITA..." "Our innovative pipeline moving very quickly... introduced seven such programs into clinic." "From capital allocation... disciplined." David Meline: "transformation efforts continue to enable both investment in business and delivery of double-digit EPS growth as we navigate our portfolio transition." Revenue growth 2%, product sales 1%, volume growth in new products outpaced declines in mature brands. "We continue to experience good volume growth in Europe at 13%... reflecting value of innovative products in market where we've experienced biosimilar competition and portfolio transition for several years." "We remain on track with plans to continue investing in pipeline building out global presence and increasing spend in support of long-term volume growth across large patient populations." Murdo: "despite increasing competition, we continue to deliver volume driven sales growth... international operations delivered 11% sales growth excluding FX driven by 15% volume growth." Discusses brands. "We continue to transition to a portfolio exemplified by volume driven growth." "I'm pleased with execution and consistency of performance in 2018, and excited about opportunities." David Reese: pipeline.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...